International Clinical Trial: Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07791186) titled 'Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years' on Aug. 25.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: BMI Korea

Condition: Prevention of COVID-19 Variant (Omicron JN.1)

Intervention: Biological: BMI2012 low-dose Other: Placebo low-dose Biological: BMI2012 mid-dose Other: Placebo mid-dose Biological: BMI2012 high-dose

Recruitment Status: Not recruiting ...